HTG Molecular Diagnostics (HTGMQ) 10-Q 8 Jun 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Jun. 01, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1169987
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,826,041

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$1,564,244	$3,613,392
Accounts receivable, net	852,285	801,125
Inventory, net allowance of $76,194 at March 31, 2015 and $54,269 at December 31, 2014	2,095,486	1,685,814
Prepaid expenses and other	122,149	112,035
Total current assets	4,634,164	6,212,366
Deferred financing and offering costs	1,742,707	1,369,281
Property and equipment:
Office equipment	417,664	414,424
Leasehold improvements	236,999	234,602
Laboratory and manufacturing equipment	2,331,857	2,009,818
Field equipment	228,124	286,044
Software	140,248	140,248
Property and equipment, gross	3,354,892	3,085,136
Less accumulated depreciation and amortization	-2,065,424	-1,938,537
Property and equipment, net	1,289,468	1,146,599
Total assets	7,666,339	8,728,246
Current liabilities:
Accounts payable	878,973	948,429
Accrued liabilities	1,692,892	1,499,750
Deferred revenue	32,015	41,248
Term loan	1,644,845	813,715
Convertible notes, less discount	2,290,178
Total current liabilities	6,538,903	3,303,142
Redeemable convertible preferred stock warrant liability	1,079,295	730,543
Term loan payable - non-current, net of discount	8,935,282	9,705,655
NuvoGen obligation - non-current	8,804,425	8,677,859
Other	51,069	58,380
Total liabilities	25,408,974	22,475,579
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	56,844,034	55,922,593
Commitments and Contingencies
Stockholders’ deficit:
Common stock, $0.001 par value; 600,000,000 shares authorized; 335,152 and 333,756 shares issued and outstanding, respectively, at March 31, 2015, 334,003 and 332,607 shares issued and outstanding , respectively, at December 31, 2014	334	333
Distributions in excess of capital	-2,255,166	-1,426,556
Treasury stock – 1,396 shares, at cost	-75,000	-75,000
Accumulated deficit	-72,256,837	-68,168,703
Total stockholders' deficit	-74,586,669	-69,669,926
Total liabilities and stockholders' deficit	7,666,339	8,728,246
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	1,402,907	1,402,687
Stockholders’ deficit:
Total stockholders' deficit	1,402,907	1,402,687
Series B Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	2,099,886	2,099,310
Stockholders’ deficit:
Total stockholders' deficit	2,099,886	2,099,310
Series C-1 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	4,568,581	4,567,525
Stockholders’ deficit:
Total stockholders' deficit	4,568,581	4,567,525
Series C-2 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	2,224,957	2,223,506
Stockholders’ deficit:
Total stockholders' deficit	2,224,957	2,223,506
Series D Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	37,787,179	37,174,666
Stockholders’ deficit:
Total stockholders' deficit	37,787,179	37,174,666
Series E Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock	8,760,524	8,454,899
Stockholders’ deficit:
Total stockholders' deficit	$8,760,524	$8,454,899

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory net allowance	$76,194	$54,269
Preferred stock, shares authorized	472,083,383
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	335,152	334,003
Common stock, shares outstanding	333,756	332,607
Treasury stock, shares	1,396	1,396
Series A Redeemable Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation value	1,406,369	1,406,369
Preferred stock, shares authorized	1,292,084	1,292,084
Preferred stock, shares issued	1,292,084	1,292,084
Preferred stock, shares outstanding	1,292,084	1,292,084
Series B Redeemable Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation value	2,104,811	2,104,811
Preferred stock, shares authorized	11,919,624	11,919,624
Preferred stock, shares issued	6,789,712	6,789,712
Preferred stock, shares outstanding	6,789,712	6,789,712
Series C-1 Redeemable Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation value	4,581,944	4,581,944
Preferred stock, shares authorized	17,530,800	17,530,800
Preferred stock, shares issued	13,242,612	13,242,612
Preferred stock, shares outstanding	13,242,612	13,242,612
Series C-2 Redeemable Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation value	2,244,343	2,244,343
Preferred stock, shares authorized	19,262,522	19,262,522
Preferred stock, shares issued	9,948,331	9,948,331
Preferred stock, shares outstanding	9,948,331	9,948,331
Series D Redeemable Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation value	68,604,412	68,604,412
Preferred stock, shares authorized	237,031,908	237,031,908
Preferred stock, shares issued	139,529,173	139,529,173
Preferred stock, shares outstanding	139,529,173	139,529,173
Series E Redeemable Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, liquidation value	$21,081,517	$21,081,517
Preferred stock, shares authorized	185,046,445	185,046,445
Preferred stock, shares issued	45,989,722	45,989,722
Preferred stock, shares outstanding	45,989,722	45,989,722

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue:
Product	$727,438	$370,007
Service	62,292	214,850
Other	234,585	241,666
Total revenue	1,024,315	826,523
Cost of revenue	894,627	642,408
Gross margin	129,688	184,115
Operating expenses:
Selling, general and administrative	3,439,269	2,076,801
Research and development	688,214	857,483
Total operating expenses	4,127,483	2,934,284
Operating loss	-3,997,795	-2,750,169
Income from change in stock warrant valuation	388,960
Interest expense	-479,299	-74,507
Other expense, net		-2,912
Net loss before income taxes	-4,088,134	-2,827,588
Net loss	-4,088,134	-2,827,588
Accretion of stock issuance costs	-24,077	-22,481
Accretion of Series E warrant discount	-87,470	-51,377
Accretion of Series D and E redeemable convertible preferred stock dividends	-798,582	-740,637
Net loss attributable to common stockholders	-4,998,263	-3,642,083
Net loss per share attributable to common stockholders, basic and diluted	($14.99)	($37.80)
Shares used in computing net loss per share attributable to common stockholders, basic and diluted	333,408	96,349
Series E Warrants
Operating expenses:
Accretion of Series E warrant discount	($87,470)	($51,377)

Condensed_Statements_of_Redeem

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders Deficit (USD $)	Total	Common Stock	Distributions In Excess of Capital	Treasury Stock	Accumulated Deficit	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series C-1 Redeemable Convertible Preferred Stock	Series C-2 Redeemable Convertible Preferred Stock	Series D Redeemable Convertible Preferred Stock	Series E Redeemable Convertible Preferred Stock
Balance at Dec. 31, 2014	($69,669,926)	$333	($1,426,556)	($75,000)	($68,168,703)	$1,402,687	$2,099,310	$4,567,525	$2,223,506	$37,174,666	$8,454,899
Balance, shares at Dec. 31, 2014		332,607
Balance, Redeemable convertible preferred stock shares at Dec. 31, 2014						1,292,084	6,789,712	13,242,612	9,948,331	139,529,173	45,938,041
Exercise of Series E warrants											11,312
Exercise of Series E warrants, shares											51,681
Exercise of stock options	4,972	1	4,971
Exercise of stock options, shares	1,149	1,149
Share-based compensation expense	76,548		76,548
Accretion of redeemable convertible preferred stock issuance costs	-24,077		-24,077			220	576	1,056	1,451	12,441	8,333
Accretion of Series E warrant discount	-87,470		-87,470								87,470
Accretion of Series D and E redeemable convertible preferred stock dividend	-798,582		-798,582							600,072	198,510
Net loss	-4,088,134				-4,088,134
Balance at Mar. 31, 2015	($74,586,669)	$334	($2,255,166)	($75,000)	($72,256,837)	$1,402,907	$2,099,886	$4,568,581	$2,224,957	$37,787,179	$8,760,524
Balance, shares at Mar. 31, 2015		333,756
Balance, Redeemable convertible preferred stock shares at Mar. 31, 2015						1,292,084	6,789,712	13,242,612	9,948,331	139,529,173	45,989,722

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities
Net loss	($4,088,134)	($2,827,588)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	151,493	119,517
Accretion of discount on NuvoGen obligation	126,566	47,500
Bad debt recovery, net	-16,146
Provision for excess inventory	21,926
Amortization of term loan deferred financing costs	3,508
Amortization of discount on term loan	36,520
Amortization of final payment premium on term loan	24,237
Amortization of discount on convertible notes	32,006
Share-based compensation	76,548	42,417
Change in redeemable convertible preferred stock warrant liability	-388,960
Amortization of convertible notes financing costs	15,107
Gain/Loss on disposal of assets	49,341
Changes in operating assets and liabilities:
Accounts receivable	-35,014	-117,818
Inventory	-431,598	-106,524
Prepaid expenses and other	-10,114	-96,165
Accounts payable	-69,456	-223,288
Accrued liabilities	83,393	-445,476
Accrued interest	13,151
Deferred revenue	-9,233	-64,548
Other long term liabilities		-112,500
Net cash used in operating activities	-4,414,859	-3,784,473
Investing activities
Purchase of property and equipment	-343,703	-126,880
Net cash used in investing activities	-343,703	-126,880
Financing activities
Proceeds from exercise of stock options	4,972
Draws on line of credit		750,000
Proceeds from exercise of E warrants	7,196
Deferred offering costs	-219,908
Deferred convertible note financing costs	-75,535
Payments on equipment lease	-7,311
Proceeds from convertible notes	3,000,000
Net cash provided by financing activities	2,709,414	8,165,552
Increase (decrease) in cash and cash equivalents	-2,049,148	4,254,199
Cash and cash equivalents at beginning of year	3,613,392	1,815,288
Cash and cash equivalents at end of period	1,564,244	6,069,487
Noncash investing and financing activities
Accretion of preferred stock issuance costs	24,077	22,481
Accretion of Series E warrant discount	87,470	51,377
Accretion of Series D and E redeemable convertible preferred stock dividends	798,582	740,637
Accrual of deferred offering and finance costs	96,598
Allocation of Series E warrant convertible notes debt discount	741,828
Supplemental cash flow information
Cash paid for interest	233,750	2,733
Series E Warrants
Noncash investing and financing activities
Exercise of Series E warrants	4,116
Accretion of Series E warrant discount	87,470	51,377
Series E Redeemable Convertible Preferred Stock
Financing activities
Proceeds from sale of preferred stock, net of issuance costs		$7,415,552

Description_of_Business

Description of Business	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business
	HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, consumables and software analytics, is used in sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge platform automates the molecular profiling of genes and gene activity using its proprietary nuclease protection chemistry on a wide variety of biological samples. The Company derives revenue from the sale of instruments, consumables and related services.
	The Company operates in one segment and its customers are primarily located in the United States. For the three months ended March 31, 2015 and 2014, approximately 4% and 32%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States.

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of March 31, 2015.  Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements.  The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented.  The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.  These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company’s final prospectus supplement filed with the SEC on May 6, 2015, and related to the Company’s Registration Statement on Form S-1/A (File No. 333-201313).
	Reverse Stock Split
	On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its common stock.  All common share and per common share information has been retroactively adjusted to reflect this reverse stock split.
	Liquidity
	The Company has had recurring operating losses and negative cash flows from operations since inception.  The Company completed its initial public offering (“IPO”) on May 11, 2015, in which it sold a total of 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million.  Additional proceeds of $1.3 million were subsequently received when an additional 90,076 shares of common stock were sold pursuant to the partial exercise by the underwriters of their over-allotment option at $14.00 per share. After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million.  The Company expects that the net proceeds from the IPO and its pre-existing cash and cash equivalents, together with interest thereon, will be sufficient to fund its operations for at least the next 12 months.  The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.  The Company expects to need to raise additional equity or debt capital at some point in the future until its revenue reaches a level sufficient to provide for self-sustaining cash flows.  There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all, or that our revenue will reach a level sufficient to provide for self-sustaining cash flows.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long lived assets and provisions for doubtful accounts, inventory obsolescence and inventory valuation.  Actual results could materially differ from those estimates.
	Accounts Receivable, net
	Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $68,922 and $85,068 at March 31, 2015 and December 31, 2014, respectively.  Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method.  There was a bad debt recovery for $16,146 and $0 for the three months ended March 31, 2015 and 2014, respectively.
	Fair Value of Financial Instruments
	The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature.  The carrying amount of the Company’s asset-secured growth capital term loan (the “Growth Term Loan”) and convertible notes were estimated using Level 3 inputs and approximates fair value since the interest rate approximates the market rate for debt securities with similar terms and risk characteristics.
	Inventory, net
	Inventory, consisting of raw materials and finished goods, is stated at the lower of cost (first-in, first-out) or market. The Company reserves or writes down its inventory for estimated obsolescence, or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
	For the three months ended March 31, 2015 the Company recorded an increase in the inventory reserve of $21,926 to adjust for estimated shrinkage and obsolescence.  For the three months ended March 31, 2014 there was no change in inventory reserve balance.
	During the quarter ended March 31, 2015, the Company determined that the average period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days and in certain circumstances the evaluation period may need to be extended beyond that period.  HTG Edge instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent agreement with the Company after evaluating for one year, the cost of the equipment is written off to cost of goods sold if the customer is allowed to continue use of the equipment.
	Prior to January 1, 2015, the Company recorded equipment under evaluation more than 90 days in property and equipment and has reclassified equipment with a net book value of $210,606 at December 31, 2014 under evaluation for longer than 90 days and less than one year from property and equipment to inventory.
	Property and Equipment, net
	Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method.  Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life.  Field equipment is amortized using the straight-line method over the lesser of the period of the related reagent agreement or the estimated useful life.  Depreciation and leasehold improvement amortization expense was $151,493 and $107,830 for the three months ended March 31, 2015 and 2014, respectively.
	Costs incurred in the development and installation of software for internal use are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed).  Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years.  In addition to the amounts above, amortization expense for capitalized software costs was $0 and $ 11,687 for the three months ended March 31, 2015 and 2014, respectively.
	Stock Issuance Costs
	Certain costs incurred in connection with the issuance of the Company’s Redeemable Convertible Preferred Stock (the “Preferred Stock”) have been deferred and are being accreted.  Stock issuance costs are accreted to distributions in excess of capital using the effective interest method.  Accretion was $24,077 and $22,481 for the three months ended March 31, 2015 and 2014, respectively.
	Deferred Financing Costs
	Certain costs incurred in connection with the Growth Term Loan have been deferred and are being amortized.  Debt issuance costs are amortized over the term of the Growth Term Loan using the effective interest method.  Costs incurred in connection with the issuance of notes under the Company’s two note and warrant purchase agreements dated December 30, 2014 (the “Note Agreements”) in February and March 2015 have been deferred and are being amortized.  These costs are being amortized over the term of the Note Agreements using the straight-line accretion method, which approximates the effective interest method in this instance.  The Company has recorded approximately $132,050 and $75,131 of deferred financing costs in the accompanying balance sheet as of March 31, 2015 and December 31, 2014.  Amortization was $18,615 and $0 for the three months ended March 31, 2015 and 2014.
	Deferred Offering Costs
	Deferred offering costs represent legal, accounting and other direct costs related to the IPO, which was completed in May 2015.  Future costs will be deferred until the completion of the initial public offering, at which time they will be reclassified to additional paid-in capital as a reduction of the proceeds.  The Company has recorded approximately $1.6 million and $1.3 million of deferred offering costs as a non-current asset in the accompanying balance sheet as of March 31, 2015 and December 31, 2014, respectively.
	Deferred Revenue
	Deferred revenue represents cash receipts for products or services to be provided in future periods.  When products are delivered or services are rendered, deferred revenue is then recognized as earned.
	Revenue Recognition
	The Company recognizes revenue from the sale of instruments, consumables and related services when the following four basic criteria are met:  (1) a contract has been entered into with a customer or persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable, and (4) collectability is reasonably assured.
	Sale of instruments and consumables
	Instrument product revenue is generally recognized upon installation and calibration by our field service engineers, unless the customer has specified any other acceptance criteria.  The sale of instruments and related installation and calibration are considered to be one unit of accounting, as instruments are required to be professionally installed and calibrated before use.  Installation generally occurs within a week of shipment.
	Consumables are considered to be separate units of accounting as they are sold separately.  Consumables revenue is recognized upon transfer of ownership, which is generally upon shipment.  The Company’s standard term and conditions provide that no right of return exists for instruments or consumables.
	When a contract involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting.  The Company performs this evaluation at the inception of an arrangement and as each item is delivered in the arrangement.  Generally, the Company accounts for a deliverable (or a group of deliverables) separately if the delivered item has stand-alone value to the customer, the customer is given a general right of return relative to the delivered item, and delivery or performance of the undelivered item or service is probable and substantially in the Company’s control. When multiple elements can be separated into separate units of accounting, arrangement consideration is allocated at the inception of the arrangement, based on each deliverables’ relative selling price. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract.
	The Company provides instruments to certain customers under a reagent agreement. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. This represents a multiple element arrangement and because all consideration under the reagent agreement is contingent on the sale of consumables, no consideration has been allocated to the instrument and no revenue has been recognized upon installation of the instrument. The cost of the instrument under the agreement is expected to be recovered in the fees charged for consumables, to the extent sold, over the term of the agreement. Revenue is recognized as consumables are shipped.
	In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. Because the pattern of revenue from the arrangement cannot be reasonably estimated, the cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of goods sold. Cost to maintain the instrument while title remains with the Company is charged to cost of sales as incurred.
	Service Revenue
	For contracts related to custom panel design services and sample processing, the Company utilizes a proportional performance revenue recognition model, under which revenue is recognized as performance occurs based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement. The Company includes all applicable costs incurred related to custom panel design services, including research and development costs and general and administrative expenses, in cost of revenue.
	The Company also provides contract research services under cost plus fixed fee government contracts. Revenue is recognized under government contracts using the percentage-of-completion method of accounting. Under the percentage-of-completion method, contract research revenue is recognized as the work progresses and services are rendered and costs are incurred. The fixed fee is recognized in proportion to costs incurred compared to total estimated costs. The Company includes all applicable costs incurred from government contracts, including general and administrative expenses on government contracts, in cost of revenue.
	Anticipated losses, if any, on contracts are charged to earnings as soon as they are identified. Anticipated losses cover all costs allocable to contracts. Revenue arising from claims or change orders is recorded either as income or as an offset against a potential loss only when the amount of the claim can be estimated and its realization is probable.
	Other Revenue
	Other revenue includes license and grant revenue.
	License revenue is generated from the licensing of the Company’s internally developed intellectual property to third parties. The revenue may be generated by nonrefundable up-front payments and license fees, milestone and other contingent payments, or royalties based on sales of commercialized products. Licensing fees are recognized on a straight-line basis over the term of the license agreement for agreements requiring specific continuing performance obligations with deferral of all or a portion of these fees. If it cannot be concluded that a license fee is fixed or determinable at the outset of an arrangement, amounts are recognized as income as payments from third parties become due. No licensing fees were included in other revenue for the three months ended March 31, 2015 and 2014.
	Grant revenue is earned when expenditures relating to the projects under these awards are incurred.
	Concentration Risks
	Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable.  The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits.  Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant.
	The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs.  The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date.
	Approximately 25%, 23% and 21% of the Company’s revenue was derived from three customers for the three months ended March 31, 2015 and 19%, 12% and 10% were derived from three customers for the three months ended March 31, 2014.  Three customers accounted for approximately 27%, 23% and 14% of the Company’s net accounts receivable as of March 31, 2015.  The Company derived 23% and 29% of its total revenue from grants and contracts, primarily from one organization during the 3 month periods ended March 31, 2015 and 2014, respectively.
	The Company currently relies on a single vendor to manufacture its HTG Edge processor and reader and additional single suppliers to supply subcomponents used in the processor.  A loss of any of these suppliers could significantly delay the delivery of HTG Edge systems, which in turn would materially affect the Company’s ability to generate revenue.
	New Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP.
	The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The FASB issued exposure drafts to change certain aspects of and delay the effective date of ASU 2014-09 by one year, but these drafts have not yet been approved.  The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and has not yet determined the method by which we will adopt the standard.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Going Concern (“ASU 2014-15”). ASU 2014-15 provides GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The standard will be effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements.
	In April 2015, the FASB issued an accounting standards update entitled “ASU 2015-03, Interest – Imputation of Interest:  Simplifying the presentation of Debt Issuance Costs”.  The standard requires entities to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability rather than as an asset, and the amortization is reported as interest expense.  The result of application of this guidance would be to reduce the deferred financing costs balance, with a corresponding reduction to the long term liabilities to which the debt issuance costs relate in the condensed balance sheets.  The standard does not affect recognition and measurement of debt issuance costs.  The Company expects to adopt ASU 2015-03 on January 1, 2016.
	Subsequent Events
	The Company has evaluated events occurring subsequent to the end of the period and determined that, other than as disclosed below, there were no other material events that require recognition or disclosure in the financial statements.
	In April 2015, the Company issued $1.5 million of convertible notes pursuant to the Note Agreements.
	On May 11, 2015, the Company completed its IPO, whereby the Company sold a total of 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million.  An additional 90,076 shares were subsequently sold pursuant to the partial exercise by the underwriters of their over-allotment option resulting in additional gross proceeds of approximately $1.3 million.  After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million.
	In connection with the initial closing of the IPO on May 11, 2015:
	·	the Company issued 710,060 shares of its Series D preferred stock upon the exercise of outstanding warrants, for which it received aggregate cash consideration of approximately $1,750 for such exercises;
	·	all outstanding shares of the Company’s convertible preferred stock were converted into 2,134,192 shares of common stock;
	·	the Company issued 374,632 shares of its common stock to the holders of the Company’s previously outstanding Series D preferred stock and Series E preferred stock in connection with the conversion of such shares into shares of the Company’s common stock as payment for accrued dividends on such shares;
	·	an aggregate of $4.5 million in outstanding principal and accrued interest under convertible promissory notes automatically converted into 324,591 shares of the Company’s common stock at a conversion price of $14.00 per share;
·	the Company’s Series C-2 preferred stock warrants and Convertible Note Warrants (See Note 9 and Note 10) converted to 1,488 and 144,772 warrants for common shares, respectively; and
·	the Company reserved 938,858 shares of common stock for future issuance under its 2014 equity incentive plan (including 12,752 shares of common stock reserved under our 2011 plan).  In addition, the Company reserved 110,820 shares of common stock for future issuance under its 2014 employee stock purchase plan.
The remaining notes under the first note Agreement and those available under the second Note Agreement were terminated in connection with the IPO.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory
	Inventory, net of reserves, consisted of the following as of the date indicated:
		March 31,		December 31,
		2015		2014
	Raw materials	$	150,040	$	174,150
	Work in process		—		—
	Finished goods		1,945,446		1,511,664
		$	2,095,486	$	1,685,814

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4. Fair Value Instruments
	Fair value measurements used by the Company for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements are based on the premise that fair value represents an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the input used in measuring fair value:
	Level 1	–	Quoted process in active markets for identical assets or liabilities on the reporting date. Financial assets in Level 1 include the amounts held in money market accounts classified as cash equivalents.
	Level 2	–	Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	–	Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. Financial liabilities in this category include the Company’s preferred stock warrants.
	The following table provides information about the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 31, 2015 and December 31, 2014, respectively:
			Balance at				Level 1		Level 2		Level 3		Balance at		Level 1		Level 2		Level 3
			March 31,										December 31,
			2015										2014
	Asset included in:
	Money Markets		$	1,816,071			$	1,816,071	$	—	$	—	$	3,608,890	$	3,608,890	$	—	$	—
	Liabilities:
	Growth Term Loan warrants		$	231,140			$	—	$	—	$	231,140	$	301,508	$	—	$	—	$	301,508
	Preferred Stock warrants		$	120,418			$	—	$	—	$	120,418	$	429,035	$	—	$	—	$	429,035
	Convertible Note warrants		$	727,737			$	—	$	—	$	727,737	$	—	$	—	$	—	$	—
	There are no other financial instruments subject to fair value measurement on a recurring basis.
	Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period.  There were no transfers between levels for the three months ended March 31, 2015 or the year ended December 31, 2014.  The Company used its May 2015 IPO pricing as an input for measurement of the fair value of its Level 3 preferred stock warrant liabilities at March 31, 2015 and the Black-Scholes option pricing model, and other valuation models for measuring the fair value of its Level 3 preferred stock warrant liabilities at December 31, 2014.
	The Company’s warrant liabilities were categorized as Level 3 because they were valued based on unobservable inputs and management judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of such financial instruments.
	The March 31, 2015 and December 31, 2014 fair value assessments used the Black-Sholes option pricing model using the following assumptions:
			March 31, 2015		December 31, 2014
	Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date		$0.01 – $0.12		$0.14 – $0.22
	Exercise price		$0.01 – $0.346		$0.01 – $0.346
	Expected risk-free interest rate		0.4 – 1.90%		1.20%
	Expected volatility		55 – 75%		70%
	Expected term		0.7 – 9.4 years		4.1 years
	Expected dividend yield		0%		0 – 8%
	The volatility assumption is based on the volatility of publicly traded industry competitors as adjusted for future expectations. The expected term was based on the Company’s historical experience and future expectations with regard to the exercise of the preferred stock warrants and the probability of conversion of the underlying preferred stock. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the warrants. At December 31, 2014 the fair value of the Company’s redeemable convertible preferred stock was determined by a valuation model that considered both income and market-based valuations of the Company’s enterprise value.
	The expected dividend yield at December 31, 2014 is consistent with the dividend rate on the Company’s redeemable convertible preferred stock. The assumptions used in the Black-Scholes option pricing model are inherently subjective and involve significant judgment. Any change in the fair value was recognized as a component of other income (expense) in the statements of operations.
	A reconciliation of the beginning and ending liabilities measured at fair value on a recurring basis using Level 3 inputs for March 31, 2015 and December 31, 2014 are as follows:
		31-Mar-15			December 31, 2014
	Beginning balance	$	730,543		$	44,120
	Issuance of Series E Warrants		—			2,190,708
	Exercise of Series E Warrants		-4,116			(1,889,201	)
	Exercise of Series D Warrants		—			(4,020	)
	Issuance of Convertible Note Warrants		741,828			—
	Change in stock warrant valuation		-388,960			388,936
	Ending balance	$	1,079,295		$	730,543

Debt_Obligations

Debt Obligations	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Obligations	Note 5. Debt Obligations.
	Growth Term Loan
	In August 2014, the Company entered into the Growth Term Loan with a syndicate of two lending institutions. The first tranche of the Growth Term Loan (“Growth Term Loan A”) of $11.0 million was funded at closing with a second tranche of $5.0 million (“Growth Term Loan B”) is available to be drawn with the completion of the Company’s IPO in May 2015 for 60 days following the effective date of the IPO. The Company received the proceeds, net of a $0.3 million original issue discount.  The Company also booked a discount for the issuance of warrants with the debt (See Note 7).  The original issuance discount and warrant discount are being amortized, using the effective interest method, over the term of the Growth Term Loan A.  Amortization expense was $0.1 million and $0 for the periods ended March 31, 2015 and 2014, respectively, and is included in interest expense in the accompanying condensed statement of operations.  The Growth Term Loan A bears interest at the fixed rate of 8.5% and matures in September 2018 and, at least through September 2015, is payable in monthly interest-only payments. The interest-only payment period is extendable through January 31, 2016, upon funding of the second tranche prior to its expiration. Following the interest-only payment period, equal monthly payments of $347,000 consisting of principal and interest amortized over the remaining term of the loan are due.  The Growth Term Loan requires the Company to maintain compliance with specific reporting covenants and does not require financial covenants.  The Growth Term Loan is secured by a lien covering substantially all of the Company’s assets, excluding patents, trademarks and other intellectual property rights (except for rights to payment related to the sale, licensing or disposition of such intellectual property rights) and certain other specified property.  The Company paid $0.1 million in financing costs upon entering the Growth Term Loan.  The agreement includes preferred stock warrants to purchase 2,512,562 shares of Series E Stock (“the “Series E Loan Warrants”) at a price of $0.2189 per share or at the purchase price of the next round of equity sold if no further shares of Series E Stock are sold.  The warrants to purchase shares of Series E Stock expire on August 22, 2024 (See Note 8).
	The principal repayments due under the term loan as of March 31, 2015, are as follows:
	2015	$	813,715
	2016		3,432,771
	2017		3,736,197
	2018		3,017,317
	Total Growth Term Loan payments		11,000,000
	Less discount		(500,311	)
	Plus final fee premium		80,438
	Total Growth Term Loan, net	$	10,580,127
	Convertible Notes
	On December 30, 2014, the Company entered into two, separate subordinated convertible promissory note agreements, (“the Note Agreements”).
	Under the first Note Agreement, the Company was able to issue up to $7,339,165 of notes to existing investors at five future, individual closings of up to $1,500,000 each upon ten days’ notice to participating investors. The date and time of the closings must be approved by the unanimous vote or written consent of those members of the Company’s Board of Directors who are not affiliated with the participating investors. When issued, the notes bear annual interest at 8% and mature on March 31, 2016. Any outstanding principal and accrued interest has automatically converted into shares of the Company’s common stock with the Company’s qualified initial public offering in May 2015. In addition, pursuant to the first Note Agreement the Company issued to participating investors warrants to purchase up to 5,029,114 shares of Series E preferred stock at $0.2189 per share, discussed further in Note 8.
	Under the second Note Agreement, the Company can issue up to $6,203,971 of subordinated convertible notes to existing investors at four future, individual closings of up to $1,703,971 each upon ten days’ notice to participating investors. The date and time of the closings must be approved by the Company’s Board of Directors, including a majority of the directors elected by the holders of the Company’s Series E Convertible Preferred Stock (the “Series E Directors”) and participating investors whose applicable closing commitment amount for such closing equals or exceeds 50% of the aggregate principal amount of the notes to be sold at such closing. When issued, the notes bear annual interest at 8% and mature on March 31, 2016. Any outstanding principal and accrued interest is automatically converted into shares of the Company’s common stock in the event of a qualified initial public offering or a private placement of preferred stock, each with gross proceeds of at least $20,000,000. In addition, pursuant to the second Note Agreement the Company issued to participating investors warrants to purchase up to 4,282,472 shares of Series E preferred stock at $0.2189 per share, discussed further in Note 8.  None of the notes under the second Note Agreement were issued prior to the IPO in May 2015.
	As of the Company’s qualified initial public offering the number of shares into which the notes will be converted is equal to the outstanding principal and accrued interest divided by the $14.00 price per share paid by investors purchasing such newly issued equity securities.
	Under each of the Note Agreements, the failure of a principal or major participating investor to invest their committed amount at each of the closings resulted in the conversion of a percentage of the investor’s preferred shares into common shares at the applicable conversion rates in effect pursuant to the Company’s restated certificate of incorporation. Under the first Note Agreement, failure of a principal investor to purchase their committed amount will resulted in the conversion of their entire holdings of preferred stock into common stock, at conversion rates then in effect. Under the second Note Agreement, up to 80% of the total preferred stock held by such investor will be converted into common stock, at conversion rates then in effect. In addition, failure to purchase the full committed amount in any closing will result in the termination of the applicable investor’s warrants, in whole or in part, and the forgiveness and extinguishment of 80% of the aggregate principal amount of the applicable investor’s outstanding notes, if any. In the event the Company sold new shares of stock in a qualified initial public offering or preferred stock in a private placement, an investor’s failure to participate in the subsequent equity financing, in an amount equal to their applicable remaining committed amount under the Note Agreements, would result in the conversion of up to 80% of the non-participating investor’s aggregate preferred stock holding as of the closing date of the subsequent equity financing, along with a reduction of up to 80% of the non-participating investor’s warrants. Pursuant to the provisions of the second Note Agreement, certain preferred shares were optionally converted into common stock as of December 30, 2014. As of March 31, 2015, all principal participating investors in the first Note Agreement had met their obligations to purchase the committed amount under the agreement.
	Certain provisions of the first Note Agreement terminated (including the investors’ obligations to purchase notes thereunder) immediately prior to the closing of the qualified initial public offering in May 2015.  Certain provisions of the second Note Agreement terminated (including the investors’ obligations to purchase notes thereunder) immediately prior to the registration statement covering a public offering of the Company’s securities under the Securities Act of 1933, as amended, becoming effective in May 2015.
	As of December 31, 2014, there were no borrowings on the Note Agreements.
	Below is a summary of the convertible notes issued as of March 31, 2015:
	Date Issued	Draw Amount			Maturity Date
	25-Feb-15	$	1,500,000		March 31, 2016
	25-Mar-15		1,500,000		March 31, 2016
	Total convertible note draws		3,000,000
	Less discount		-709,822
	Total convertible notes, net	$	2,290,178
	The Company booked a discount for the estimated fair value of warrants issued in connection with the debt (See Note 8).  The warrant discount is being amortized, using the effective interest method, over the term of the Convertible Notes.  Amortization expense was $32,006 and $0 for the periods ended March 31, 2015 and 2014, respectively, and is included in interest expense in the accompanying condensed statement of operations.

Other_Agreements

Other Agreements	3 Months Ended
	Mar. 31, 2015
Other Agreements [Abstract]
Other Agreements	Note 6. Other Agreements
	NuvoGen Obligation
	The Company entered into an asset purchase agreement (the “Agreement”) in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition.  However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. The Company exchanged upfront consideration of 600,000 shares of the Company’s common stock. The remaining cash consideration of $15,000,000 is to be paid by the Company through a percentage of applicable annual sales equal to the greater of a minimum annual payment or 6% of the Company’s applicable annual revenues. The obligation is non-interest bearing and was secured by certain patents and trademarks.  Certain terms of the agreement were amended in November 2012 and February 2014.
	The Company recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. Unamortized debt discount was $438,067 and $564,634 at March 31, 2015 and December 31, 2014, respectively.
	Pursuant to the closing of the Growth Term Loan in August 2014 (See Note 5), the Company agreed to accelerate certain minimum payments pursuant to the Agreement and NuvoGen agreed to terminate its security interest in the originally pledged patents and trademarks. Remaining minimum payments that were otherwise due for 2014, 2015 and the first quarter of 2016, amounting to $868,750 were paid in advance. No further payment is due under the Agreement until the second quarter of 2016. The acceleration of payments did not significantly change the minimum cash flows and therefore had no significant accounting effect.
	Payments to NuvoGen during the three months ended March 31, 2015 and 2014 were $0 and $425,000, respectively. Discount accreted during the three months ended March 31, 2015 and 2014 was $126,566 and $47,500 respectively.
	The remaining payments due to NuvoGen at March 31, 2015, are as follows:
	2015	$	—
	2016		543,750
	2017		800,000
	2018		400,000
	2019		400,000
	2020 and beyond		7,098,743
		$	9,242,493
	Illumina, Inc. Agreement
	In October 2014, the Company entered into a development and component supply agreement with Illumina for the development and worldwide commercialization by the Company of up to two complete diagnostic gene expression profiling tests for with Illumina’s diagnostic instruments, using components supplied by Illumina. The Company refers to these diagnostic gene expression profiling tests as IVD test kits. The IVD test kits may be used in two discrete testing fields chosen by the Company, one or both of which may relate to oncology for breast, lung, lymphoma or melanoma tumors, and up to one of which may relate to transplant, chronic obstructive pulmonary disease, or immunology/autoimmunity. The Company provided notice to Illumina of its first testing selections during the quarter ended March 31, 2015.  If a second selection is to be elected, the Company must provide notice to Illumina of the Company’s second selected field within 24 months following the date of the agreement.
	Following the Company’s selection of the testing field for each IVD test kit, the Company and Illumina have agreed to negotiate a development plan for the development and regulatory approval of the applicable IVD test kit, under which development and regulatory support will be provided by Illumina. Upon mutual agreement of the first development plan, the Company will pay Illumina a fixed fee in the six-figure dollar range. The Company is also required to pay Illumina up to $1.0 million in the aggregate upon achievement of specified regulatory milestones relating to the IVD test kits. In addition, the Company has agreed to pay Illumina a single digit percentage royalty on net sales of any IVD test kits that the Company commercializes pursuant to the agreement. As of March 31, 2015 the first development plan has not been completed. Ongoing research and development costs for these programs have been expensed as incurred and $0 has been paid to Illumina relating to this agreement.
	The agreement will expire in October 2019 or on the date which the last to expire development plan under the agreement is completed, whichever is earlier. The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share
	Note 7. Net Loss Per Share
	Net loss attributable to common stockholders per share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Outstanding stock options, warrants and preferred stock have not been included in the calculation of diluted net loss attributable to common stockholders per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share:
		For the 3-months ended
		March 31,
		2015			2014
	Numerator:
	Net loss	$	(4,088,134	)	$	(2,827,588	)
	Accretion of stock issuance costs		(24,077	)		(22,481	)
	Accretion of discount on Series E warrants		(87,470	)		(51,377	)
	Series E and D, preferred stock dividends		(798,582	)		(740,637	)
	Net loss attributable to common stockholders	$	(4,998,263	)	$	(3,642,083	)
	Denominator:
	Weighted-average common shares outstanding-basic and		333,408			96,349
	diluted
	The following outstanding options, warrants and preferred stock were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:
		March 31,			December 31,
		2015			2014
	Options to purchase common stock		593,663			595,577
	Convertible preferred stock (as converted)		2,127,463			2,126,982
	Convertible preferred stock warrants (as converted)		136,908			50,681
	Common stock warrant		931			931

Preferred_Stock_Warrants

Preferred Stock Warrants	3 Months Ended
	Mar. 31, 2015
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Preferred Stock Warrants	Note 8.  Preferred Stock Warrants
	On August 22, 2014, in connection with the Company’s entry into the Growth Term Loan, the Company issued to the lenders Series E Loan Warrants exercisable for an aggregate of 2,512,562 shares of Series E preferred stock at a price of $0.2189 per share. The warrants provide for cashless exercise at the option of the holders, and also contain provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the completion of the initial public offering in May 2015, the Series E Loan Warrants will become exercisable for an aggregate of 23,396 shares of the Company’s common stock at an exercise price of $23.51 per share. The Series E Loan Warrants expire by their terms on August 22, 2024, provided that the warrants will be automatically exercised on a cashless basis upon expiration if not previously exercised if the fair market value of a share of the Company’s common stock exceeds the per share exercise price.
	The Company allocated the total proceeds of the Growth Term Loan and the Series E Loan Warrants based on the residual value method. Assumptions used to determine the initial fair value included fair value of shares of Series E Stock on grant date $0.31; Exercise price $0.2189; Expected risk-free interest rate 1.6%; Expected volatility 70.0%; Expected term 4.5 years; and Expected dividend yield 8.0%. The fair value of the Series E Warrants of $0.12 per share, or $301,507, was recorded as a discount on the Growth Term Loan to be accreted over the term of the Growth Term Loan using the effective interest method. The Company has accounted for the Series E Loan Warrants as liabilities as such warrants are indexed to shares that could be redeemed for cash outside the control of the Company. The preferred Warrants were valued using quoted market prices from the Company’s May 2015 IPO at March 31, 2015 and using the Black-Scholes option pricing model as of December 31, 2014.  Refer to Note 4 for assumptions used to value these warrants.  At March 31, 2015 and December 31, 2014, the fair value of the Series E Loan Warrants was $231,140 and $301,508, respectively.
	On December 30, 2014, in connection with the Company’s Note and Warrant Purchase Agreements (Note 5) the Company agreed to issue warrants (the “Convertible Note Warrants”) exercisable for an aggregate of 9,311,586 shares of Series E Stock at a price of $0.2189 per share, for aggregate consideration of $1,354. The Convertible Note Warrants were issued on January 15, 2015. The warrants provide for cashless exercise at the option of the holders, and also contain provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the completion of the IPO in May 2015, the Convertible Note Warrants will become exercisable for shares of the Company’s common stock at the initial public offering price of $14.00 per share. The Convertible Note Warrants expire by their terms on January 15, 2022. As the Convertible Note Warrants were issued in conjunction with and in order to establish a lending facility commitment, they are being accounted for as a debt discount to be amortized over the life of the Note Agreements using the effective interest method and as a warrant liability, at fair value, as they are indexed to shares that could be redeemed for cash outside the control of the Company.
	The Company recorded the initial $741,828 of the Convertible Note Warrants using the Black-Scholes option pricing model and assumptions further described in Note 4, specifically using a 7 year term, a 1.6% risk free interest rate, 75% volatility, 0% dividend yield and a common stock price of $0.13 which is a pre-IPO equivalent to the Company’s $14.00 per share offering price in May 2015, which the Company considered to approximate the fair value at January 14, 2015 and March 31, 2015 as the operations of the business had not changed during the intervening period. At March 31, 2015, the Company revalued the Convertible Note Warrants to $727,737 using the Black-Scholes option pricing model and specifically using a 6.5 year term, a 1.7% risk free interest rate, 75% volatility, 0% dividend yield and a common stock price of $0.13 per share.

Redeemable_Convertible_Preferr

Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Redeemable Convertible Preferred Stock	Note 9. Redeemable Convertible Preferred Stock
	On February 4, 2014, the Company entered into the Series E Preferred Stock and Warrant Purchase Agreement (the “Series E Agreement”) authorizing the sale and issuance of up to 99,132,024 shares of its Series E Stock for $0.2189 per share and warrants (the “Series E Warrants”) to purchase up to an aggregate of 33,044,008 shares of Series E Stock at an exercise price of $0.001 per share. Pursuant to the Series E Agreement, up to 49,566,012 shares of Series E Stock together with Series E Warrants to purchase up to an aggregate of 16,522,004 shares of Series E Stock would be offered at one or more closings of a first tranche and the remainder of which will be offered in a second tranche.
	As a result of the Series E Preferred Agreement, the Company’s authorized shares were increased to 600,000,000 shares of Common Stock and 472,083,383 shares of Preferred Stock.
	On February 4, 2014 the Company issued 34,099,476 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for every three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 11,366,486 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. Together with the Series E Warrants, the issuance of shares of Series E Stock and Series E Warrants resulted in gross proceeds to the Company of $7,476,879.
	On March 31, 2014, pursuant to a rights offering, the Company issued 354,062 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for each three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 118,017 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. Together with Series E Warrants, the issuance of shares of Series E Stock and Series E Warrants resulted in gross proceeds to the Company of $77,634. The Series E Agreement provides for a second tranche on or before November 30, 2014, contingent upon the achievement of certain milestones.
	It was determined that, given the nominal strike price of the Series E Warrants and the fact that the Series E Preferred Warrants were required to be exercised immediately upon issuance, the per share value of the Series E Warrants would be similar to the effective per share value of the Series E Stock, or $0.1645 per share.
	The second closing under the Series E Agreement, originally scheduled to occur on or before November 31, 2014, was replaced by an alternative financing in the form of subordinated convertible promissory notes as discussed further in Note 5.
	The Series A/B/C/D Stock and Series E Stock have a par value of $0.001 per share. In the event of a liquidation of the Company (“Liquidation Event”), the holders of the Series D Stock and Series E Stock are entitled to preferential distributions of any of the assets of the Company.
	The Series D Stock and Series E Stock liquidation preference is equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared. In the event of a Liquidation Event, payment of dividends, or share redemption, the holders of Series E Stock have preference over the holders of the Series A/B/C/D Stock and the Common Stock. The holders of Series D Stock have preference over the holders of Series A/B/C Stock and Common Stock. After the payment in full of the Series E Stock and Series D Stock liquidation preferences, the holders of preferred stock and common stock then outstanding will share ratably in the distribution of net assets of the Company available for distribution, with each share of preferred stock being deemed, for such purpose, to be equal to the number of shares of common stock into which it is convertible the day before such distribution, provided that the Series D Stock maximum participation amount would not exceed four times the Series D Stock original issue price, or $0.8756. A Liquidation Event is considered to occur upon any reorganization, merger, consolidation, sale, or capital stock transfer, whereby the preferred stockholders of record prior to the transition will immediately, after the transaction, hold less than 50% of the voting power of the surviving entity. At least 60% of the holders of Series E Stock and a majority of the Series E Directors may deem any of the aforementioned Liquidation Events as void by giving notice to the Company five days before the potential Liquidation Event. The Company is accreting up to the redemption amount and not the liquidation value, because additional amounts due under the liquidation rights are not considered probable at initial recording or at March 31, 2015 and December 31, 2014.
	The shares of Series A/B/C/D Stock and Series E Stock are convertible into Common Stock based on their original issue price, excluding any accrued but unpaid dividends. The shares of Series A/B/C/D Stock and Series E Stock are convertible into Common Stock at any time at the option of the holder at the then-applicable conversion rate. The Series A/B/C/D Stock and Series E Stock will automatically be converted into Common Stock at the then-applicable conversion rate as of the earlier of the close of a firm commitment underwritten public offering resulting in gross proceeds to the Company of at least $30,000,000 and three times the Series E Stock original issue price, or at the election of the Board of Directors and at least 60% of the holders of Series E Stock. Series D Stock and Series E Stock share conversion prices are subject to adjustment if the Company issues any additional shares of Common Stock or preferred stock at a price less than the applicable Series D Stock and Series E Stock share conversion price in effect immediately prior to the issuance of Common Stock or Preferred Stock. Immediately prior to the IPO, the requisite election of the Board of Directors and the holder of Series E Stock was obtained and the shares of preferred stock were converted into shares of common stock.  Also see Note 2.  None of these contingent conversion price adjustments resulted in a beneficial conversion feature at March 31, 2015 or December 31, 2014.
	The shares of Series A/B/C/D Stock and Series E Stock each have the right to redemption or their respective class of shares on a date beginning not prior to February 2019 (the “Series E Preferred Stock Redemption Date”). In order to effect each respective redemption, the holders of at least 60% of the voting power of the then outstanding shares of Series D Stock or Series E Stock need to vote in favor of a Series D or Series E Stock redemption and provide written notice to the Company at least sixty days prior to the Series E Preferred Stock Redemption Date of such election. The holders of at least a majority in the voting power of the then outstanding shares of Series A/B/C Stock may then vote in favor of a Series A/B/C Stock redemption, respectively. The holders of at least 66 2/3% of the voting power of the then outstanding shares of Series A Redeemable Convertible Preferred Stock (the “Series A Stock”) may then vote in favor of a Series A Stock redemption. The Series D Stock and Series E Stock redemption value is equal to the Series D Stock and Series E Stock original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all dividends declared but unpaid thereon together with any accruing dividends accrued but unpaid thereon, whether or not declared, with respect to such shares. The Series A/B/C Stock redemption value is equal to the respective series original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all accrued and unpaid dividends with respect to such shares. If the Company does not have sufficient funds or other assets legally available to redeem all shares to be redeemed at any redemption date, it shall redeem as applicable (i) pro rata to Series E Stock, until all shares are redeemed, (ii) pro rata to Series D Stock until all shares are redeemed, (iii) pro rata to Series C Stock, until all shares are redeemed, (iv) pro rata to Series A Stock and Series B Stock, until all shares are redeemed. If any shares to be redeemed remain outstanding, the Company shall redeem the remaining shares in accordance with the previous sentence as soon as sufficient funds are legally available. Due to the redemption feature, the preferred shares are recorded as mezzanine equity.
	As of March 31, 2015, current Series A Stock, Series B Stock, Series C-1 Stock, Series C-2 Stock, Series D Stock and Series E Stock conversion ratios were 0.030, 0.011, 0.014, 0.009, 0.009 and 0.009, respectively, after consideration of the one-for-107.39 reverse split. If converted at March 31, 2015, all of the outstanding preferred shares would convert into 2,127,463 shares of Common Stock.
	The Company has accounted for the Series E Warrants as liabilities as such warrants are indexed to shares that could be redeemed for cash outside the control of the Company. The Company allocated the total proceeds first to the Series E Warrants based on their fair value of approximately $1,890,000 and the remainder amounting to approximately $5,665,000 of the proceeds allocated to the Preferred Shares. The fair value of the Series E Warrants was estimated to approximate the fair value of the Series E Stock because of their nominal price. The amount allocated to the Series E Warrants represents a discount to the Preferred Shares and will be accreted using the effective interest method up to the redemption amount from the respective issuance date to redemption date of five years. Accretion for the three months ended March 31, 2015 and 2014 was approximately $87,000 and $0, respectively. Upon immediate exercise of the Series E Warrants, the amount recorded as warrant liability was reclassified to Preferred Shares, and issuance costs of $48,384 which had been allocated to the warrants were expensed. The Company is not accreting to the amount resulting from additional liquidation preference rights under the agreement because they are not considered probable at initial recording or at March 31, 2015. The Company additionally analyzed the issuance of Series E Warrants with the Series E Stock, noting there was no resulting beneficial conversion feature.
	The Company’s Series D Stock and Series E Stock accrue cumulative dividends at 8% per annum on the original issue price of $0.2189, whether or not declared by the Board of Directors. In connection with the Company’s Growth Term Loan, the holders of both the Series D Stock and Series E Stock agreed to waive their rights to cash dividends. As a result, only a share dividend, based on the cumulative dividends divided by the original issue price, is to be paid upon declaration by the Board of Directors or upon the automatic conversion of the Company’s Preferred Stock. Dividends are accreted based on the number of days outstanding. At March 31, 2015 and December 31, 2014, the cumulative Series D Stock and Series E Stock dividends were $8,440,716 and $7,643,378, respectively. The Series D Stock and Series E Stock accruing dividends may only be paid in additional shares of Series D Preferred Stock or Series E Preferred Stock or in underlying common stock (on as converted method) when preferred shares are converted, as approved by the holders of at least 60% of the outstanding shares of Series E Preferred, which approval was obtained on August 22, 2014.
	After payment of the accruing dividends above, any additional dividend payment (other than dividends on shares of Common Stock payable in shares of Common Stock approved by at least a majority of the Series E Directors) shall be distributed among the holders of the Preferred Stock and Common Stock then outstanding pro rata based on the number of shares of Common Stock then held by each holder (assuming conversion of all such Preferred Stock into Common Stock at the then effective conversion prices). The Company cannot declare or pay any dividends on the Company’s Series A Stock, Series B Stock, Series C Stock or Common Stock (collectively, the “Junior Stock”) unless at the same time an equivalent or greater dividend is declared or paid on all outstanding shares of the Series D Stock and Series E Stock (the “Senior Preferred”), and all accruing dividends then accrued on outstanding shares of Senior Preferred have been paid in full. There were no dividends declared by the Board of Directors through March 31, 2015. The holders of Series A/B/C/D Stock and Series E Stock are also entitled to the number of votes equal to the number of shares of Common Stock into which the shares of Series A/B/C Stock shares are convertible.
	The following shares of redeemable convertible preferred stock have been issued by the Company as of March 31, 2015:
		Years	Shares			Net
		Issued	Issued			Proceeds
	Series A Stock	2002 – 2004		1,292,084		$	1,307,794
	Series B Stock	2005 – 2006		11,919,624			3,542,237
	Series C-1 Stock	2007		16,240,450			5,505,641
	Series C-2 Stock	2008 – 2009		19,104,610			4,172,672
	Series D Stock	2011 – 2015		143,762,592			30,947,799
	Series E Stock	2014 – 2015		45,989,722			7,395,228
	The value of the shares of Series A/B/C/D Stock and Series E Stock is recorded at the amount initially received on the date of issuance or upon conversion from debt, less any applicable discounts for warrants and issuance costs, adjusted for the accretion of discounts utilizing the effective interest method up to the redemption amount from the respective issuance date to the Series E Preferred Stock Redemption Date, and the accretion of cumulative dividends. The redemption value for Series A/B/C Stock agrees to the liquidation value presented on face of the balance sheet. The redemption value of Series D Stock and Series E Stock is $38,061,476 and $11,003,054 respectively.
	In accordance with a provision of the Note Agreements (Note 5), the failure of a principal or major participating investor to commit to or invest their otherwise committed amount at each stage of future convertible note closings results in a conversion of a portion of the non-participating holder’s preferred shares at the applicable conversion rates in effect pursuant to the Company’s restated certificate of incorporation. In December 2014, certain investors chose not to participate in closings under the second Note Agreement. As a result, 80% of all shares of Preferred Stock held by these non-participating holders were converted into Common Stock on a seniority basis, with each holder’s most senior series of Preferred Stock converting first, followed by the conversion of the holder’s next most senior series, and so forth, until the requisite number of preferred shares had been converted into Common Stock. The total share impact of this optional conversion is shown below. The following shares of Preferred Stock were optionally converted to Common Stock as of December 30, 2014:
		Preferred		Common
		Shares		Stock
		Converted		Equivalents
	Series B Stock	5,129,912			57,307
	Series C-1 Stock	2,997,838			43,330
	Series C-2 Stock	9,156,279			86,292
	Series D Stock	4,233,419			39,420
	On January 30, 2015, 51,681 shares of Series E stock were purchased by a convertible note warrant holder for $0.2189 per share.

Stock_Option_Plan

Stock Option Plan	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Plan
	Note 10. Stock Option Plan
	In February 2014, pursuant to the Series E Agreement, the amount of shares reserved under the 2011 Plan was increased to 20% of the total outstanding shares of the Company calculated on a fully diluted basis. The shares reserved under the 2011 Plan were required to be kept at that percentage with each subsequent equity financing. At March 31, 2015, the number of shares reserved for future issuance under the 2011 plan is 12,752.
	As of March 31, 2015, options to purchase 593,663 shares of Common Stock were outstanding, including 324,189 options that are fully vested. The remaining options vest over 2.4 years.
	A summary of the Plans’ stock option activity is as follows:
		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average Exercise			Average		Intrinsic Value
				Price Per Share			Remaining
							Contractual Life
							(Years)
	Balance at December 31, 2014	595,577		$	3.71		7.8
	Granted	—
	Exercised	(1,149	)		4.32
	Forfeited	(765	)		8.65
	Balance at March 31, 2015	593,663			3.7		7.5	$		6,114,729
	Vested and expected to vest at March 31, 2015	583,536			3.69		7.5	$		6,016,256
	Exercisable at March 31, 2015	324,189		$	3.39		6.4	$		3,439,645
	Below is a summary of stock option grant activity and related fair value information for the three months ended March 31, 2014:
	2014 Grants	Options			Exercise		Fair Value of
		Granted			Price		Common Stock on
							Date of Grant
	January	2,094		$	2.15	$	2.15
	March	249,361		$	2.15	$	2.15
	Total	251,455
	There were no stock options granted during the three months ended March 31, 2015.
	As of March 31, 2015, there was total unrecognized compensation expense of $628,473 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 3 years.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. Commitments and Contingencies
	Legal Matters
	The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote.
	Severance Agreements and Retention Plans
	In October 2012, the Board of Directors and 60% of requisite preferred holders approved a plan to set aside no less than 15% of the proceeds of any sale of the Company to be distributed to the Company’s employees, directors or consultants as designated by the Board of Directors (the “HTG Employee Retention Plan”).  The HTG Employee Retention Plan will terminate pursuant to its terms upon the closing of the Company’s initial public offering.
	The Company has entered into employment agreements or other arrangements with certain named executive officers and have adopted an Employee Retention Plan for select participants, which provide salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreements or arrangements.
	Indemnification Agreements
	In the course of operating our business, we have entered into, and continue to enter into, separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our amended and restated bylaws.  These agreements may require us indemnify our directors and executive officers for certain expenses incurred by a director executive officer in any action or proceeding arising out of their services as one of our directors or executive officers.
	Merck Non-Exclusive License Agreement
	In June 2012, the Company entered into a non-exclusive license agreement with Merck Sharp & Dohme Cor. (“Merck”) whereby the Company agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology.  The Company agreed to pay Merck certain contingent milestone payments between $50,000 and $1,000,000 and future royalties of 3%-6% of sales derived from such products developed that utilize the licensed technology.  No amounts have been accrued or paid under this agreement as the Company has not achieved any of the milestone targets or developed any products that utilize the licensed technology.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes
	Note 12. Income Taxes
	The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively.
	In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any Federal or state income tax benefit in the statements of operations.
	The Company periodically reviews its filing positions for all open tax years in all U.S. Federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports.
	The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the “more likely than not” criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at March 31, 2015 or December 31, 2014.
	The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at March 31, 2015 and December 31, 2014, respectively, and has not recognized interest or penalties during the three months ended March 31, 2015 and 2014, respectively, since there are no material unrecognized tax benefits. Management believes no material change to the amount of unrecognized tax benefits will occur within in the next 12 months.

RelatedParty_Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Note 13.  Related-Party Transactions
	In March 2014 and July 2013, the Company entered into two separate consulting agreements to assess potential markets for its products with a holder of Series D Stock and Series E Stock. The stockholder was paid $0 and $11,000 for the three months ended March 31, 2015 and 2014, respectively under those agreements.  An employee of the stockholder is a member of the Board of Directors.  At March 31, 2015, there were no further amounts due under the consulting agreements.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of March 31, 2015.  Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements.  The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented.  The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.  These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2014, included in the Company’s final prospectus supplement filed with the SEC on May 6, 2015, and related to the Company’s Registration Statement on Form S-1/A (File No. 333-201313).
Reverse Stock Split	Reverse Stock Split
	On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its common stock.  All common share and per common share information has been retroactively adjusted to reflect this reverse stock split.
Liquidity	Liquidity
	The Company has had recurring operating losses and negative cash flows from operations since inception.  The Company completed its initial public offering (“IPO”) on May 11, 2015, in which it sold a total of 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million.  Additional proceeds of $1.3 million were subsequently received when an additional 90,076 shares of common stock were sold pursuant to the partial exercise by the underwriters of their over-allotment option at $14.00 per share. After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million.  The Company expects that the net proceeds from the IPO and its pre-existing cash and cash equivalents, together with interest thereon, will be sufficient to fund its operations for at least the next 12 months.  The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.  The Company expects to need to raise additional equity or debt capital at some point in the future until its revenue reaches a level sufficient to provide for self-sustaining cash flows.  There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all, or that our revenue will reach a level sufficient to provide for self-sustaining cash flows.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long lived assets and provisions for doubtful accounts, inventory obsolescence and inventory valuation.  Actual results could materially differ from those estimates.
	Accounts Receivable, net
	Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $68,922 and $85,068 at March 31, 2015 and December 31, 2014, respectively.  Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method.  There was a bad debt recovery for $16,146 and $0 for the three months ended March 31, 2015 and 2014, respectively.
Accounts Receivable, net	Accounts Receivable, net
	Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $68,922 and $85,068 at March 31, 2015 and December 31, 2014, respectively.  Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method.  There was a bad debt recovery for $16,146 and $0 for the three months ended March 31, 2015 and 2014, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature.  The carrying amount of the Company’s asset-secured growth capital term loan (the “Growth Term Loan”) and convertible notes were estimated using Level 3 inputs and approximates fair value since the interest rate approximates the market rate for debt securities with similar terms and risk characteristics.
Inventory, net	Inventory, net
	Inventory, consisting of raw materials and finished goods, is stated at the lower of cost (first-in, first-out) or market. The Company reserves or writes down its inventory for estimated obsolescence, or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.
	For the three months ended March 31, 2015 the Company recorded an increase in the inventory reserve of $21,926 to adjust for estimated shrinkage and obsolescence.  For the three months ended March 31, 2014 there was no change in inventory reserve balance.
	During the quarter ended March 31, 2015, the Company determined that the average period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days and in certain circumstances the evaluation period may need to be extended beyond that period.  HTG Edge instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent agreement with the Company after evaluating for one year, the cost of the equipment is written off to cost of goods sold if the customer is allowed to continue use of the equipment.
	Prior to January 1, 2015, the Company recorded equipment under evaluation more than 90 days in property and equipment and has reclassified equipment with a net book value of $210,606 at December 31, 2014 under evaluation for longer than 90 days and less than one year from property and equipment to inventory.
Property and Equipment, net	Property and Equipment, net
	Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method.  Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life.  Field equipment is amortized using the straight-line method over the lesser of the period of the related reagent agreement or the estimated useful life.  Depreciation and leasehold improvement amortization expense was $151,493 and $107,830 for the three months ended March 31, 2015 and 2014, respectively.
	Costs incurred in the development and installation of software for internal use are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed).  Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years.  In addition to the amounts above, amortization expense for capitalized software costs was $0 and $ 11,687 for the three months ended March 31, 2015 and 2014, respectively.
Stock Issuance Cost	Stock Issuance Costs
	Certain costs incurred in connection with the issuance of the Company’s Redeemable Convertible Preferred Stock (the “Preferred Stock”) have been deferred and are being accreted.  Stock issuance costs are accreted to distributions in excess of capital using the effective interest method.  Accretion was $24,077 and $22,481 for the three months ended March 31, 2015 and 2014, respectively.
Deferred Financing Costs	Deferred Financing Costs
	Certain costs incurred in connection with the Growth Term Loan have been deferred and are being amortized.  Debt issuance costs are amortized over the term of the Growth Term Loan using the effective interest method.  Costs incurred in connection with the issuance of notes under the Company’s two note and warrant purchase agreements dated December 30, 2014 (the “Note Agreements”) in February and March 2015 have been deferred and are being amortized.  These costs are being amortized over the term of the Note Agreements using the straight-line accretion method, which approximates the effective interest method in this instance.  The Company has recorded approximately $132,050 and $75,131 of deferred financing costs in the accompanying balance sheet as of March 31, 2015 and December 31, 2014.  Amortization was $18,615 and $0 for the three months ended March 31, 2015 and 2014.
Deferred Offering Costs	Deferred Offering Costs
	Deferred offering costs represent legal, accounting and other direct costs related to the IPO, which was completed in May 2015.  Future costs will be deferred until the completion of the initial public offering, at which time they will be reclassified to additional paid-in capital as a reduction of the proceeds.  The Company has recorded approximately $1.6 million and $1.3 million of deferred offering costs as a non-current asset in the accompanying balance sheet as of March 31, 2015 and December 31, 2014, respectively.
Deferred Revenue	Deferred Revenue
	Deferred revenue represents cash receipts for products or services to be provided in future periods.  When products are delivered or services are rendered, deferred revenue is then recognized as earned.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue from the sale of instruments, consumables and related services when the following four basic criteria are met:  (1) a contract has been entered into with a customer or persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable, and (4) collectability is reasonably assured.
	Sale of instruments and consumables
	Instrument product revenue is generally recognized upon installation and calibration by our field service engineers, unless the customer has specified any other acceptance criteria.  The sale of instruments and related installation and calibration are considered to be one unit of accounting, as instruments are required to be professionally installed and calibrated before use.  Installation generally occurs within a week of shipment.
	Consumables are considered to be separate units of accounting as they are sold separately.  Consumables revenue is recognized upon transfer of ownership, which is generally upon shipment.  The Company’s standard term and conditions provide that no right of return exists for instruments or consumables.
	When a contract involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting.  The Company performs this evaluation at the inception of an arrangement and as each item is delivered in the arrangement.  Generally, the Company accounts for a deliverable (or a group of deliverables) separately if the delivered item has stand-alone value to the customer, the customer is given a general right of return relative to the delivered item, and delivery or performance of the undelivered item or service is probable and substantially in the Company’s control. When multiple elements can be separated into separate units of accounting, arrangement consideration is allocated at the inception of the arrangement, based on each deliverables’ relative selling price. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract.
	The Company provides instruments to certain customers under a reagent agreement. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. This represents a multiple element arrangement and because all consideration under the reagent agreement is contingent on the sale of consumables, no consideration has been allocated to the instrument and no revenue has been recognized upon installation of the instrument. The cost of the instrument under the agreement is expected to be recovered in the fees charged for consumables, to the extent sold, over the term of the agreement. Revenue is recognized as consumables are shipped.
	In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. Because the pattern of revenue from the arrangement cannot be reasonably estimated, the cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of goods sold. Cost to maintain the instrument while title remains with the Company is charged to cost of sales as incurred.
	Service Revenue
	For contracts related to custom panel design services and sample processing, the Company utilizes a proportional performance revenue recognition model, under which revenue is recognized as performance occurs based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement. The Company includes all applicable costs incurred related to custom panel design services, including research and development costs and general and administrative expenses, in cost of revenue.
	The Company also provides contract research services under cost plus fixed fee government contracts. Revenue is recognized under government contracts using the percentage-of-completion method of accounting. Under the percentage-of-completion method, contract research revenue is recognized as the work progresses and services are rendered and costs are incurred. The fixed fee is recognized in proportion to costs incurred compared to total estimated costs. The Company includes all applicable costs incurred from government contracts, including general and administrative expenses on government contracts, in cost of revenue.
	Anticipated losses, if any, on contracts are charged to earnings as soon as they are identified. Anticipated losses cover all costs allocable to contracts. Revenue arising from claims or change orders is recorded either as income or as an offset against a potential loss only when the amount of the claim can be estimated and its realization is probable.
	Other Revenue
	Other revenue includes license and grant revenue.
	License revenue is generated from the licensing of the Company’s internally developed intellectual property to third parties. The revenue may be generated by nonrefundable up-front payments and license fees, milestone and other contingent payments, or royalties based on sales of commercialized products. Licensing fees are recognized on a straight-line basis over the term of the license agreement for agreements requiring specific continuing performance obligations with deferral of all or a portion of these fees. If it cannot be concluded that a license fee is fixed or determinable at the outset of an arrangement, amounts are recognized as income as payments from third parties become due. No licensing fees were included in other revenue for the three months ended March 31, 2015 and 2014.
	Grant revenue is earned when expenditures relating to the projects under these awards are incurred.
Concentration Risks	Concentration Risks
	Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable.  The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits.  Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant.
	The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs.  The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date.
	Approximately 25%, 23% and 21% of the Company’s revenue was derived from three customers for the three months ended March 31, 2015 and 19%, 12% and 10% were derived from three customers for the three months ended March 31, 2014.  Three customers accounted for approximately 27%, 23% and 14% of the Company’s net accounts receivable as of March 31, 2015.  The Company derived 23% and 29% of its total revenue from grants and contracts, primarily from one organization during the 3 month periods ended March 31, 2015 and 2014, respectively.
	The Company currently relies on a single vendor to manufacture its HTG Edge processor and reader and additional single suppliers to supply subcomponents used in the processor.  A loss of any of these suppliers could significantly delay the delivery of HTG Edge systems, which in turn would materially affect the Company’s ability to generate revenue.
New Accounting Pronouncements	New Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP.
	The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The FASB issued exposure drafts to change certain aspects of and delay the effective date of ASU 2014-09 by one year, but these drafts have not yet been approved.  The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and has not yet determined the method by which we will adopt the standard.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Going Concern (“ASU 2014-15”). ASU 2014-15 provides GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The standard will be effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements.
	In April 2015, the FASB issued an accounting standards update entitled “ASU 2015-03, Interest – Imputation of Interest:  Simplifying the presentation of Debt Issuance Costs”.  The standard requires entities to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability rather than as an asset, and the amortization is reported as interest expense.  The result of application of this guidance would be to reduce the deferred financing costs balance, with a corresponding reduction to the long term liabilities to which the debt issuance costs relate in the condensed balance sheets.  The standard does not affect recognition and measurement of debt issuance costs.  The Company expects to adopt ASU 2015-03 on January 1, 2016.
Subsequent Events	Subsequent Events
	The Company has evaluated events occurring subsequent to the end of the period and determined that, other than as disclosed below, there were no other material events that require recognition or disclosure in the financial statements.
	In April 2015, the Company issued $1.5 million of convertible notes pursuant to the Note Agreements.
	On May 11, 2015, the Company completed its IPO, whereby the Company sold a total of 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million.  An additional 90,076 shares were subsequently sold pursuant to the partial exercise by the underwriters of their over-allotment option resulting in additional gross proceeds of approximately $1.3 million.  After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million.
	In connection with the initial closing of the IPO on May 11, 2015:
	·	the Company issued 710,060 shares of its Series D preferred stock upon the exercise of outstanding warrants, for which it received aggregate cash consideration of approximately $1,750 for such exercises;
	·	all outstanding shares of the Company’s convertible preferred stock were converted into 2,134,192 shares of common stock;
	·	the Company issued 374,632 shares of its common stock to the holders of the Company’s previously outstanding Series D preferred stock and Series E preferred stock in connection with the conversion of such shares into shares of the Company’s common stock as payment for accrued dividends on such shares;
	·	an aggregate of $4.5 million in outstanding principal and accrued interest under convertible promissory notes automatically converted into 324,591 shares of the Company’s common stock at a conversion price of $14.00 per share;
	·	the Company’s Series C-2 preferred stock warrants and Convertible Note Warrants (See Note 9 and Note 10) converted to 1,488 and 144,772 warrants for common shares, respectively; and
	·	the Company reserved 938,858 shares of common stock for future issuance under its 2014 equity incentive plan (including 12,752 shares of common stock reserved under our 2011 plan).  In addition, the Company reserved 110,820 shares of common stock for future issuance under its 2014 employee stock purchase plan.
	The remaining notes under the first note Agreement and those available under the second Note Agreement were terminated in connection with the IPO.

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of reserves, consisted of the following as of the date indicated:
		March 31,		December 31,
		2015		2014
	Raw materials	$	150,040	$	174,150
	Work in process		—		—
	Finished goods		1,945,446		1,511,664
		$	2,095,486	$	1,685,814

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table provides information about the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 31, 2015 and December 31, 2014, respectively:
			Balance at				Level 1		Level 2		Level 3		Balance at		Level 1		Level 2		Level 3
			March 31,										December 31,
			2015										2014
	Asset included in:
	Money Markets		$	1,816,071			$	1,816,071	$	—	$	—	$	3,608,890	$	3,608,890	$	—	$	—
	Liabilities:
	Growth Term Loan warrants		$	231,140			$	—	$	—	$	231,140	$	301,508	$	—	$	—	$	301,508
	Preferred Stock warrants		$	120,418			$	—	$	—	$	120,418	$	429,035	$	—	$	—	$	429,035
	Convertible Note warrants		$	727,737			$	—	$	—	$	727,737	$	—	$	—	$	—	$	—
Summary of Fair Value Assessment of Warrant Liability Inputs using Black Sholes Option Pricing Model	The March 31, 2015 and December 31, 2014 fair value assessments used the Black-Sholes option pricing model using the following assumptions:
			March 31, 2015		December 31, 2014
	Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date		$0.01 – $0.12		$0.14 – $0.22
	Exercise price		$0.01 – $0.346		$0.01 – $0.346
	Expected risk-free interest rate		0.4 – 1.90%		1.20%
	Expected volatility		55 – 75%		70%
	Expected term		0.7 – 9.4 years		4.1 years
	Expected dividend yield		0%		0 – 8%
Reconciliation of Beginning and Ending Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending liabilities measured at fair value on a recurring basis using Level 3 inputs for March 31, 2015 and December 31, 2014 are as follows:
		31-Mar-15			December 31, 2014
	Beginning balance	$	730,543		$	44,120
	Issuance of Series E Warrants		—			2,190,708
	Exercise of Series E Warrants		-4,116			(1,889,201	)
	Exercise of Series D Warrants		—			(4,020	)
	Issuance of Convertible Note Warrants		741,828			—
	Change in stock warrant valuation		-388,960			388,936
	Ending balance	$	1,079,295		$	730,543

Debt_Obligations_Tables

Debt Obligations (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Principal Repayments Due Under Term Loan	The principal repayments due under the term loan as of March 31, 2015, are as follows:
	2015	$	813,715
	2016		3,432,771
	2017		3,736,197
	2018		3,017,317
	Total Growth Term Loan payments		11,000,000
	Less discount		(500,311	)
	Plus final fee premium		80,438
	Total Growth Term Loan, net	$	10,580,127
Summary of the Convertible Notes Issued	Below is a summary of the convertible notes issued as of March 31, 2015:
	Date Issued	Draw Amount			Maturity Date
	25-Feb-15	$	1,500,000		March 31, 2016
	25-Mar-15		1,500,000		March 31, 2016
	Total convertible note draws		3,000,000
	Less discount		-709,822
	Total convertible notes, net	$	2,290,178

Other_Agreements_Tables

Other Agreements (Tables)	3 Months Ended
	Mar. 31, 2015
Other Agreements [Abstract]
Schedule of Remaining Payments Due	The remaining payments due to NuvoGen at March 31, 2015, are as follows:
	2015	$	—
	2016		543,750
	2017		800,000
	2018		400,000
	2019		400,000
	2020 and beyond		7,098,743
		$	9,242,493

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share:
		For the 3-months ended
		March 31,
		2015			2014
	Numerator:
	Net loss	$	(4,088,134	)	$	(2,827,588	)
	Accretion of stock issuance costs		(24,077	)		(22,481	)
	Accretion of discount on Series E warrants		(87,470	)		(51,377	)
	Series E and D, preferred stock dividends		(798,582	)		(740,637	)
	Net loss attributable to common stockholders	$	(4,998,263	)	$	(3,642,083	)
	Denominator:
	Weighted-average common shares outstanding-basic and		333,408			96,349
	diluted
Outstanding Options, Warrants and Preferred Stock Excluded from Computation of Diluted Net Loss per Share	The following outstanding options, warrants and preferred stock were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:
		March 31,			December 31,
		2015			2014
	Options to purchase common stock		593,663			595,577
	Convertible preferred stock (as converted)		2,127,463			2,126,982
	Convertible preferred stock warrants (as converted)		136,908			50,681
	Common stock warrant		931			931

Redeemable_Convertible_Preferr1

Redeemable Convertible Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Summary of Redeemable Convertible Preferred Stock	The following shares of redeemable convertible preferred stock have been issued by the Company as of March 31, 2015:
		Years	Shares			Net
		Issued	Issued			Proceeds
	Series A Stock	2002 – 2004		1,292,084		$	1,307,794
	Series B Stock	2005 – 2006		11,919,624			3,542,237
	Series C-1 Stock	2007		16,240,450			5,505,641
	Series C-2 Stock	2008 – 2009		19,104,610			4,172,672
	Series D Stock	2011 – 2015		143,762,592			30,947,799
	Series E Stock	2014 – 2015		45,989,722			7,395,228
Schedule of Conversion of Preferred Stock into Common Stock	The following shares of Preferred Stock were optionally converted to Common Stock as of December 30, 2014:
		Preferred		Common
		Shares		Stock
		Converted		Equivalents
	Series B Stock	5,129,912			57,307
	Series C-1 Stock	2,997,838			43,330
	Series C-2 Stock	9,156,279			86,292
	Series D Stock	4,233,419			39,420

Stock_Option_Plan_Tables

Stock Option Plan (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Plans Activity	A summary of the Plans’ stock option activity is as follows:
		Number of		Weighted-			Weighted-		Aggregate
		Shares		Average Exercise			Average		Intrinsic Value
				Price Per Share			Remaining
							Contractual Life
							(Years)
	Balance at December 31, 2014	595,577		$	3.71		7.8
	Granted	—
	Exercised	(1,149	)		4.32
	Forfeited	(765	)		8.65
	Balance at March 31, 2015	593,663			3.7		7.5	$		6,114,729
	Vested and expected to vest at March 31, 2015	583,536			3.69		7.5	$		6,016,256
	Exercisable at March 31, 2015	324,189		$	3.39		6.4	$		3,439,645
Summary of Stock Option Grant Activity and Fair Value Information
	Below is a summary of stock option grant activity and related fair value information for the three months ended March 31, 2014:
	2014 Grants	Options			Exercise		Fair Value of
		Granted			Price		Common Stock on
							Date of Grant
	January	2,094		$	2.15	$	2.15
	March	249,361		$	2.15	$	2.15
	Total	251,455

Description_of_Business_Additi

Description of Business - Additional Information (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Significant Accounting Policies [Line Items]
Number of operating segments	1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	4.00%	32.00%

Basis_of_Presentation_and_Summ2

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	3 Months Ended			12 Months Ended		0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Feb. 04, 2014	Apr. 27, 2015	11-May-15	Apr. 30, 2015
Significant Accounting Policies [Line Items]
Allowance for Doubtful Accounts Receivable	$68,922	$85,068		$85,068
Bad debt expense	16,146	0
Change in inventory valuation reserves	21,926		0
Reclassified equipment with a net book value				210,606
Depreciation and leasehold improvement amortization expense	151,493		107,830
Amortization expense for capitalized software costs	0		11,687
Accretion of preferred stock issuance costs	24,077		22,481
Deferred financing costs	132,050	75,131		75,131
Debt issuance cost amortization	18,615		0
Deferred offering costs, noncurrent	1,600,000	1,300,000		1,300,000
Licenses revenue fees				0	0
Convertible preferred stock converted into common stock	2,127,463
Common stock, shares issued	335,152	334,003		334,003
Common Stock, Value, Issued	334	333		333
Series C-2 Preferred Stock Warrants
Significant Accounting Policies [Line Items]
Conversion of stock, shares issued				86,292
Series D Redeemable Convertible Preferred Stock
Significant Accounting Policies [Line Items]
Reverse stock split of common stock	0.009
Conversion of stock, shares issued				39,420
Series E Preferred Stock Warrants
Significant Accounting Policies [Line Items]
Reverse stock split of common stock	0.009					1
Common stock shares sold						354,062	34,099,476
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	25.00%		19.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage	23.00%		12.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage	21.00%		10.00%
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	27.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage	23.00%
Accounts Receivable | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage	14.00%
Revenue from grants and contracts | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Sales revenue percentage	23.00%		29.00%
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life	3 years
Minimum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life	3 years
Maximum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life	5 years
Subsequent Event
Significant Accounting Policies [Line Items]
Reverse stock split of common stock								0.0093
Convertible notes payable issued										1,500,000
Common stock, at the initial public offering price per shares									$14
Subsequent Event | IPO
Significant Accounting Policies [Line Items]
Common stock shares sold									3,570,000
Common stock, at the initial public offering price per shares									$14
Gross proceeds from initial public offering									50,000,000
Net proceeds from initial public offering after underwriters' fees, commissions and offering costs									45,400,000
Convertible preferred stock converted into common stock									2,134,192
Subsequent Event | IPO | Convertible Note One
Significant Accounting Policies [Line Items]
Conversion price per share									$14
Conversion of stock, shares issued									324,591
Conversion of stock, amount converted									4,500,000
Subsequent Event | IPO | Series C-2 Preferred Stock Warrants
Significant Accounting Policies [Line Items]
Convertible preferred stock converted into warrants									1,488
Subsequent Event | IPO | Series D Redeemable Convertible Preferred Stock
Significant Accounting Policies [Line Items]
Common stock, shares issued									710,060
Common Stock, Value, Issued									1,750
Subsequent Event | IPO | Series E Preferred Stock Warrants
Significant Accounting Policies [Line Items]
Convertible preferred stock exercisable for purchase of common stock									144,772
Subsequent Event | IPO | Series E Preferred Stock Warrants | Growth Term Loan
Significant Accounting Policies [Line Items]
Convertible preferred stock converted into warrants									374,632
Subsequent Event | IPO | Two Thousand Fourteen Incentive Plan
Significant Accounting Policies [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance									938,858
Subsequent Event | IPO | Two Thousand Eleven Plan
Significant Accounting Policies [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance									12,752
Subsequent Event | IPO | Two Thousand Fourteen Employee Stock Purchase Plan
Significant Accounting Policies [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance									110,820
Subsequent Event | Over-Allotment Option
Significant Accounting Policies [Line Items]
Common stock shares sold									90,076
Proceeds from issuance of common stock									$1,300,000

Inventory_Schedule_of_Inventor

Inventory - Schedule of Inventory (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$150,040	$174,150
Finished goods	1,945,446	1,511,664
Inventory, net	$2,095,486	$1,685,814

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2015	Dec. 31, 2014
Money Markets
Asset included in:
Financial Assets	$1,816,071	$3,608,890
Level 1 | Money Markets
Asset included in:
Financial Assets	1,816,071	3,608,890
Preferred Stock Warrants
Liabilities:
Financial Liabilities	120,418	429,035
Preferred Stock Warrants | Level 3
Liabilities:
Financial Liabilities	120,418	429,035
Convertible Note Warrants
Liabilities:
Financial Liabilities	727,737
Convertible Note Warrants | Level 3
Liabilities:
Financial Liabilities	727,737
Warrant
Liabilities:
Financial Liabilities	231,140	301,508
Warrant | Level 3
Liabilities:
Financial Liabilities	$231,140	$301,508

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Summary of Fair Value Assessment of Warrant Liability Inputs using Black Sholes Option Pricing Model (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2014	Mar. 25, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	$0.13	$0.13	$0.13
Expected risk-free interest rate	1.70%	1.60%	1.20%
Expected volatility	75.00%	75.00%	70.00%
Expected term	6 years 6 months	7 years	4 years 1 month 6 days
Expected dividend yield	0.00%	0.00%
Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date		$0.14	$0.14	$0.01
Exercise price		$0.01	$0.01	$0.01
Expected risk-free interest rate	0.40%
Expected volatility	55.00%
Expected term	8 months 12 days
Expected dividend yield			0.00%
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date		$0.22	$0.22	$0.12
Exercise price		$0.35	$0.35	$0.35
Expected risk-free interest rate	1.90%
Expected volatility	75.00%
Expected term	9 years 4 months 24 days
Expected dividend yield			8.00%

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Liabilities Measured at Fair Value on Recurring Basis (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$730,543	$44,120
Issuance of warrants	741,828
Change in stock warrant valuation	-388,960	388,936
Ending balance	1,079,295	730,543
Series E Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Issuance of warrants		2,190,708
Exercise of warrants	-4,116	-1,889,201
Series D Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Exercise of warrants		($4,020)

Debt_Obligations_Additional_In

Debt Obligations - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended		1 Months Ended
	Dec. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Aug. 31, 2014	Aug. 22, 2014
	Agreement			Institution
Debt Obligations [Line Items]
Debt instrument, amortization expense		$126,566	$47,500
Financing costs		219,908
Number of convertible promissory note agreements	2
Accrued interest	$14
Debt conversion, converted instrument, rate	80.00%
Extinguishment of debt as percentage of principal amount	80.00%
Investor equity with warrants percentage	80.00%
Debt Instrument, Convertible, Terms of Conversion Feature		As of the Companybs qualified initial public offering the number of shares into which the notes will be converted is equal to the outstanding principal and accrued interest divided by the $14.00 price per share paid by investors purchasing such newly issued equity securities. Under each of the Note Agreements, the failure of a principal or major participating investor to invest their committed amount at each of the closings resulted in the conversion of a percentage of the investorbs preferred shares into common shares at the applicable conversion rates in effect pursuant to the Companybs restated certificate of incorporation. Under the first Note Agreement, failure of a principal investor to purchase their committed amount will resulted in the conversion of their entire holdings of preferred stock into common stock, at conversion rates then in effect. Under the second Note Agreement, up to 80% of the total preferred stock held by such investor will be converted into common stock, at conversion rates then in effect. In addition, failure to purchase the full committed amount in any closing will result in the termination of the applicable investorbs warrants, in whole or in part, and the forgiveness and extinguishment of 80% of the aggregate principal amount of the applicable investorbs outstanding notes, if any. In the event the Company sold new shares of stock in a qualified initial public offering or preferred stock in a private placement, an investorbs failure to participate in the subsequent equity financing, in an amount equal to their applicable remaining committed amount under the Note Agreements, would result in the conversion of up to 80% of the non-participating investorbs aggregate preferred stock holding as of the closing date of the subsequent equity financing, along with a reduction of up to 80% of the non-participating investorbs warrants. Pursuant to the provisions of the second Note Agreement, certain preferred shares were optionally converted into common stock as of December 30, 2014. As of March 31, 2015, all principal participating investors in the first Note Agreement had met their obligations to purchase the committed amount under the agreement.
Amortization of warrant discount		87,470	51,377
Convertible Debt
Debt Obligations [Line Items]
Amortization of warrant discount		32,006	0
Series E Redeemable Convertible Preferred Stock
Debt Obligations [Line Items]
Proceeds from sale of preferred stock, net of issuance costs			7,415,552
Growth Term Loan
Debt Obligations [Line Items]
Number of loan lending institutions				2
Financing costs				100,000
Growth Term Loan | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share				2,512,562
Class of warrant or right per share price				$0.22
Warrants expiration date				22-Aug-24
Growth Term Loan A
Debt Obligations [Line Items]
Term loan payable					11,000,000
Debt instrument, amortization expense		100,000	0
Debt instrument, fixed rate				8.50%
Debt instrument, description		The interest-only payment period is extendable through January 31, 2016, upon funding of the second tranche prior to its expiration.
Monthly periodic payment				347,000
Growth Term Loan A | Maximum
Debt Obligations [Line Items]
Debt instrument, maturity date		30-Sep-18
Growth Term Loan A | Minimum
Debt Obligations [Line Items]
Debt instrument, maturity date		30-Sep-15
Growth Term Loan B
Debt Obligations [Line Items]
Term loan payable				5,000,000
Debt issuance costs				300,000
Convertible Note One
Debt Obligations [Line Items]
Debt instrument, fixed rate	8.00%
Debt instrument, maturity date		31-Mar-16
Issuance of notes to existing investors	7,339,165
Number of future issued to existing investors	5
Closing value	1,500,000
Number of days of notice to participating investors	10 days
Convertible Note One | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share	5,029,114
Class of warrant or right per share price	$0.22
Convertible Note Two
Debt Obligations [Line Items]
Debt instrument, fixed rate	8.00%
Debt instrument, maturity date		31-Mar-16
Issuance of notes to existing investors	6,203,971
Number of future issued to existing investors	4
Closing value	1,703,971
Number of days of notice to participating investors	10 days
Percentage of aggregate principal amount	50.00%
Conversion percentage	80.00%
Convertible Note Two | Series E Redeemable Convertible Preferred Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share	4,282,472
Class of warrant or right per share price	$0.22
Convertible Note Two | Minimum | IPO
Debt Obligations [Line Items]
Proceeds from issuance of common stock	20,000,000
Convertible Note Two | Minimum | Private Placement
Debt Obligations [Line Items]
Proceeds from sale of preferred stock, net of issuance costs	$20,000,000

Debt_Obligations_Principal_Rep

Debt Obligations - Principal Repayments Due Under Term Loan (Details) (USD $)	Mar. 31, 2015
Debt Instrument [Line Items]
Less discount	($709,822)
Term Loan
Debt Instrument [Line Items]
2015	813,715
2016	3,432,771
2017	3,736,197
2018	3,017,317
Total Growth Term Loan payments	11,000,000
Less discount	-500,311
Plus final fee premium	80,438
Total Growth Term Loan, net	$10,580,127

Debt_Obligations_Summary_of_Co

Debt Obligations - Summary of Convertible Notes Issued (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Debt Instrument [Line Items]
Convertible note draws	$3,000,000
Less discount	-709,822
Total convertible notes, net	2,290,178
Convertible Note One
Debt Instrument [Line Items]
Date Issued	25-Feb-15
Maturity Date	31-Mar-16
Convertible note draws	1,500,000
Convertible Note Two
Debt Instrument [Line Items]
Date Issued	25-Mar-15
Maturity Date	31-Mar-16
Convertible note draws	$1,500,000

Other_Agreements_Additional_In

Other Agreements - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock	600,000
Remaining cash consideration to be paid	$15,000,000
Percentage on annual revenues for cash consideration to be paid	6.00%
Discount rate used to calculate asset purchase obligation	2.50%
Unamortized debt discount	709,822
Payments on obligation	0	425,000
Accretion of discount on Nuvogen obligation	126,566	47,500
Research and development	688,214	857,483
Agreement expiration date	31-Oct-19
Description on termination of agreement	The Company may terminate the agreement at any time upon 90 daysb written notice and may terminate any development plan under the agreement upon 30 daysb prior written notice. Illumina may terminate the agreement upon 30 daysb prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other partybs material breach of the agreement that remains uncured for 30 days, or upon the other partybs bankruptcy
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000
Research and development	0
Growth Term Loan
Other Agreements [Line Items]
Minimum payments of pledged intangible assets due in 2014	868,750
Minimum payments of pledged intangible assets due in 2015	868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	0
Nuvogen
Other Agreements [Line Items]
Unamortized debt discount	$438,067		$564,634

Other_Agreements_Schedule_of_R

Other Agreements - Schedule of Remaining Payments Due (Details) (Nuvo Gen Asset Purchase Agreement, USD $)	Mar. 31, 2015
Nuvo Gen Asset Purchase Agreement
Purchase Obligation Fiscal Year Maturity [Line Items]
2016	$543,750
2017	800,000
2018	400,000
2019	400,000
2020 and beyond	7,098,743
Total	$9,242,493

Net_Loss_per_Share_Reconciliat

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net loss	($4,088,134)	($2,827,588)
Accretion of stock issuance costs	-24,077	-22,481
Accretion of Series E warrant discount	-87,470	-51,377
Series E and D, preferred stock dividends	-798,582	-740,637
Net loss attributable to common stockholders	-4,998,263	-3,642,083
Denominator:
Weighted-average common shares outstanding-basic and diluted	333,408	96,349
Series E Warrants
Numerator:
Accretion of Series E warrant discount	($87,470)	($51,377)

Net_Loss_per_Share_Outstanding

Net Loss per Share - Outstanding Options, Warrants and Preferred Stock Excluded from Computation of Diluted Net Loss per Share (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Convertible preferred stock (as converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	2,127,463	2,126,982
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	593,663	595,577
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	931	931
Warrant | Convertible preferred stock (as converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	136,908	50,681

Preferred_Stock_Warrants_Addit

Preferred Stock Warrants - Additional Information (Details) (USD $)	3 Months Ended		12 Months Ended	0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2014	Aug. 22, 2014	Jan. 15, 2015	11-May-15	31-May-15
Class Of Warrant Or Right [Line Items]
Share price	$0.13	$0.13	$0.13
Expected risk-free interest rate	1.70%	1.60%	1.20%
Expected volatility	75.00%	75.00%	70.00%
Expected term	6 years 6 months	7 years	4 years 1 month 6 days
Expected dividend yield	0.00%	0.00%
Fair value of warrants	$727,737	$741,828	$741,828
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	$0.13	$0.13	$0.13
Subsequent Event
Class Of Warrant Or Right [Line Items]
Common stock, at the initial public offering price per shares						$14
Series E Stock
Class Of Warrant Or Right [Line Items]
Share price				$0.31
Warrants exercise price				$0.22
Expected risk-free interest rate				1.60%
Expected volatility				70.00%
Expected term				4 years 6 months
Expected dividend yield				8.00%
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date				$0.31
Series E Loan Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares				2,512,562			23,396
Warrants exercise price				$0.22			$23.51
Warrants expiration date	22-Aug-24
Warrants exercise price				$0.12
Fair value of warrants	231,140	301,508	301,508	301,507
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares					9,311,586
Warrants exercise price					$0.22
Warrants expiration date	14-Jan-22
Aggregate consideration					$1,354

Redeemable_Convertible_Preferr2

Redeemable Convertible Preferred Stock - Additional Information (Details) (USD $)	0 Months Ended		3 Months Ended	12 Months Ended
	Mar. 31, 2014	Feb. 04, 2014	Mar. 31, 2015	Dec. 31, 2014	Jan. 30, 2015	Aug. 22, 2014
Class Of Stock [Line Items]
Common stock, shares authorized			600,000,000	600,000,000
Preferred stock, shares authorized			472,083,383
Outstanding convertible preferred stock			2,127,463
Fair value of warrants			$727,737	$741,828
Dividends declared			0
Non-participating Holders
Class Of Stock [Line Items]
Percentage of preferred stock converted into common stock				80.00%
Preferred Stock
Class Of Stock [Line Items]
Fair value of warrants			5,665,000
Minimum
Class Of Stock [Line Items]
Liquidation Event Voting Power Of Surviving Entity Percentage			50.00%
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, shares authorized		99,132,024
Convertible preferred stock, price per share	$0.22	$0.22	$0.22
Preferred stock, shares authorized			185,046,445	185,046,445
Issuance of preferred stock, net of issuance cost, shares	354,062	34,099,476
Common stock, conversion basis	1		0.009
Preferred stock par value, per share			$0.00
Liquidation preference			The Series D Stock and Series E Stock liquidation preference is equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared. In the event of a Liquidation Event, payment of dividends, or share redemption, the holders of Series E Stock have preference over the holders of the Series A/B/C/D Stock and the Common Stock.
Stock holders voting percentage required for stock redemption			60.00%
Preferred stock cumulative dividend percentage			8.00%
Preferred stock cumulative dividends				7,643,378
Voting power of outstanding shares						60.00%
Preferred stock redemption value			11,003,054
Stock purchased by convertible note warrant holder, shares					51,681
Stock purchased by convertible note warrant holder price per share					$0.22
Series A Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized			1,292,084	1,292,084
Common stock, conversion basis			0.03
Preferred stock par value, per share			$0.00
Stock holders voting percentage required for stock redemption			66.67%
Series B Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized			11,919,624	11,919,624
Common stock, conversion basis			0.011
Preferred stock par value, per share			$0.00
Series C Preferred Stock
Class Of Stock [Line Items]
Preferred stock par value, per share			$0.00
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share			$0.22
Preferred stock, shares authorized			237,031,908	237,031,908
Common stock, conversion basis			0.009
Preferred stock par value, per share			$0.00
Liquidation Event Voting Power Of Surviving Entity Percentage			60.00%
Liquidation preference			The Series D Stock and Series E Stock liquidation preference is equal to two times the original issue price of the Series D Stock or Series E Stock, respectively, plus any accrued but unpaid dividends whether or not declared. In the event of a Liquidation Event, payment of dividends, or share redemption, the holders of Series E Stock have preference over the holders of the Series A/B/C/D Stock and the Common Stock.
Preferred stock cumulative dividend percentage			8.00%
Preferred stock cumulative dividends			8,440,716
Preferred stock redemption value			38,061,476
Series D Redeemable Convertible Preferred Stock | Maximum
Class Of Stock [Line Items]
Series D Stock original issue price			$0.88
A B C D Stock And Series E Stock
Class Of Stock [Line Items]
Underwritten public offering resulting in gross proceeds			30,000,000
Stock holders voting percentage required for stock redemption			60.00%
Series C-1
Class Of Stock [Line Items]
Common stock, conversion basis			0.014
Series C-2
Class Of Stock [Line Items]
Common stock, conversion basis			0.009
Series E Warrant
Class Of Stock [Line Items]
Purchase of warrant exercise price per share		$0.00
Purchase price of preferred stock per Series E warrant	$0.00	$0.00
Warrants exercise price	$0.00	$0.00
Financial institution warrant issued, share	118,017	11,366,486
Proceeds from Issuance of preferred stock and warrants	77,634	7,476,879
Fair value of warrants			1,890,000
Warrant Issuance Costs			$48,384
Preferred stock accreted redemption period			5 years
Series E Warrant | Maximum
Class Of Stock [Line Items]
Financial institution warrant issued, share		33,044,008
Series E Warrant | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share			$0.16
Tranche One | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Financial institution warrant issued, share		49,566,012
Tranche One | Series E Warrant
Class Of Stock [Line Items]
Financial institution warrant issued, share		16,522,004

Redeemable_Convertible_Preferr3

Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock , Years Issued	2002 b 2004
Redeemable convertible preferred stock , Shares Issued	1,292,084
Redeemable convertible preferred stock , Net Proceeds	$1,307,794
Series B Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock , Years Issued	2005 b 2006
Redeemable convertible preferred stock , Shares Issued	11,919,624
Redeemable convertible preferred stock , Net Proceeds	3,542,237
Series C-1 Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock , Years Issued	2007
Redeemable convertible preferred stock , Shares Issued	16,240,450
Redeemable convertible preferred stock , Net Proceeds	5,505,641
Series C-2 Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock , Years Issued	2008 b 2009
Redeemable convertible preferred stock , Shares Issued	19,104,610
Redeemable convertible preferred stock , Net Proceeds	4,172,672
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock , Years Issued	2011 b 2015
Redeemable convertible preferred stock , Shares Issued	143,762,592
Redeemable convertible preferred stock , Net Proceeds	30,947,799
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable convertible preferred stock , Years Issued	2014 b 2015
Redeemable convertible preferred stock , Shares Issued	45,989,722
Redeemable convertible preferred stock , Net Proceeds	$7,395,228

Redeemable_Convertible_Preferr4

Redeemable Convertible Preferred Stock - Schedule of Conversion of Preferred Stock into Common Stock (Details)	12 Months Ended
	Dec. 31, 2014
Series B Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion, Preferred Shares Converted	5,129,912
Conversion of stock, shares issued	57,307
Series C-1 Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion, Preferred Shares Converted	2,997,838
Conversion of stock, shares issued	43,330
Series C-2 Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion, Preferred Shares Converted	9,156,279
Conversion of stock, shares issued	86,292
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion, Preferred Shares Converted	4,233,419
Conversion of stock, shares issued	39,420

Stock_Option_Plan_Additional_I

Stock Option Plan - Additional Information (Details) (USD $)	1 Months Ended		3 Months Ended		1 Months Ended
	Mar. 31, 2014	Jan. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2014	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of options			2 years 4 months 24 days
Options to purchase common stock outstanding			593,663			595,577
Options fully vested			324,189
Options Granted	249,361	2,094	0	251,455
Unrecognized compensation expense			$628,473
Compensation expense related to unvested stock options, period expected to be recognized			3 years
Employee Stock Option | Two Thousand Eleven Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance						12,752
Percentage of increase on outstanding shares					20.00%

Stock_Option_Plan_Summary_of_S

Stock Option Plan - Summary of Stock Option Plans Activity (Details) (USD $)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2014	Jan. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Beginning Balance			595,577
Number of Shares, Granted	249,361	2,094	0	251,455
Number of Shares, Exercised			-1,149
Number of Shares, Forfeited			-765
Number of Shares, Ending Balance			593,663		595,577
Number of Shares, Vested and expected to vest			583,536
Number of Shares, Exercisable			324,189
Weighted-Average Exercise Price Per Share, Beginning Balance			$3.71
Weighted-Average Exercise Price Per Share, Granted	$2.15	$2.15
Weighted-Average Exercise Price Per Share, Exercised			$4.32
Weighted-Average Exercise Price Per Share, Forfeited			$8.65
Weighted-Average Exercise Price Per Share, Ending Balance			$3.70		$3.71
Weighted-Average Exercise Price Per Share, Vested and expected to vest			$3.69
Weighted-Average Exercise Price Per Share, Exercisable			$3.39
Weighted-Average Remaining Contractual Life, Outstanding			7 years 9 months 18 days		6 years 4 months 24 days
Weighted-Average Remaining Contractual Life, Vested and excepted to vest			7 years 8 months 12 days
Weighted-Average Remaining Contractual Life, Exercisable			6 years 3 months 18 days
Aggregate Intrinsic Value, Ending Balance			$6,114,729
Aggregate Intrinsic Value, Vested and expected to vest			6,016,256
Aggregate Intrinsic Value, Exercisable			$3,439,645

Stock_Option_Plan_Summary_of_S1

Stock Option Plan - Summary of Stock Option Grant Activity and Related Fair Value Information (Details) (USD $)	1 Months Ended		3 Months Ended
	Mar. 31, 2014	Jan. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Granted	249,361	2,094	0	251,455
Exercise Price	$2.15	$2.15
Fair Value of Common Stock on Date of Grant	$2.15	$2.15

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Details) (USD $)	1 Months Ended
	Oct. 31, 2012	Jun. 30, 2012
Commitments And Contingencies [Line Items]
Percentage of requisite preferred holders who approved plan to set aside proceeds of any sale of to be distributed	60.00%
Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, milestone accrued or paid		$0
Minimum
Commitments And Contingencies [Line Items]
Percentage of proceeds of any sale to be distributed to employees, directors, or consultants	15.00%
Minimum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments		50,000
Non-exclusive license agreement, future royalties		3.00%
Maximum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments		$1,000,000
Non-exclusive license agreement, future royalties		6.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement	Greater than 50 percent
Accrued interest or penalties	$0	$0
Recognized interest or penalties	$0	$0

RelatedParty_Transactions_Addi

Related-Party Transactions - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Number of consulting agreement	2
Series D Stock
Related Party Transaction [Line Items]
Consulting fees paid to stockholder	$0
Series E Stock
Related Party Transaction [Line Items]
Consulting fees paid to stockholder		$11,000